share_log
Breakings ·  May 28 20:05
Outlook Therapeutics Inc - Lytenava™ (Bevacizumab Gamma) Receives Ten Years of Market Exclusivity in EU
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment